Australian biotech firm Echo IQ saw a 25% surge in stock price after receiving FDA clearance for its AI-driven cardiovascular diagnostic tool. The company is set to capitalize on commercial opportunities in the U.S. healthcare market with innovative solutions like EchoSolv AS.